A group of health experts warned against a genetic test recently approved by the U.S. Food and Drug Administration (FDA) that claims to be able to identify a person’s risk of opioid addiction, noting that the test may produce false results.
The FDA approved the AvertD test in December, stating it was the “first test that uses DNA in assessing whether certain individuals may have an elevated risk of developing opioid use disorder (OUD).” In an April 4 letter to the agency, a group of scientists asked the FDA to revoke the approval, noting that the test “does not predict genetic risk” of opioid addiction.
